TY - JOUR
T1 - Reducing time to differentiated service delivery for newly diagnosed people living with HIV in Kigali, Rwanda
T2 - Study protocol for a pilot, unblinded, randomised controlled study
AU - Ross, Jonathan
AU - Murenzi, Gad
AU - Hill, Sarah
AU - Remera, Eric
AU - Ingabire, Charles
AU - Umwiza, Francine
AU - Munyaneza, Athanase
AU - Muhoza, Benjamin
AU - Habimana, Dominique Savio
AU - Mugwaneza, Placidie
AU - Zhang, Chenshu
AU - Yotebieng, Marcel
AU - Anastos, Kathryn
N1 - Funding Information:
Funding This work was supported by the US National Institute of Mental Health (K23 MH114752); by the US National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health and the National Institute on Drug Abuse, as part of Central Africa IeDEA (U01 AI096299); and by the Einstein-Rockefeller-CUNY Center for AIDS Research (P30 AI124414), which is supported by the following NIH cofunding and participating institutes and centres: National Institute of Allergy and Infectious Diseases, National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Heart, Lung and Blood Institute, National Institute on Drug Abuse, National Institute of Mental Health, National Institute on Aging, Fogarty International Center, and Office of AIDS Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The study is sponsored by Montefiore Medical Center (111 E. 210th St., Bronx, NY 10467, +1.718.920.4321). The study sponsor and funder have no role in the study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication.
Funding Information:
This work was supported by the US National Institute of Mental Health (K23 MH114752); by the US National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health and the National Institute on Drug Abuse, as part of Central Africa IeDEA (U01 AI096299); and by the Einstein-Rockefeller-CUNY Center for AIDS Research (P30 AI124414), which is supported by the following NIH cofunding and participating institutes and centres: National Institute of Allergy and Infectious Diseases, National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Heart, Lung and Blood Institute, National Institute on Drug Abuse, National Institute of Mental Health, National Institute on Aging, Fogarty International Center, and Office of AIDS Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The study is sponsored by Montefiore Medical Center (111 E. 210th St., Bronx, NY 10467, +1.718.920.4321). The study sponsor and funder have no role in the study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication.
Publisher Copyright:
©
PY - 2021/4/24
Y1 - 2021/4/24
N2 - Introduction Current HIV guidelines recommend differentiated service delivery (DSD) models that allow for fewer health centre visits for clinically stable people living with HIV (PLHIV). Newly diagnosed PLHIV may require more intensive care early in their treatment course, yet frequent appointments can be burdensome to patients and health systems. Determining the optimal parameters for defining clinical stability and transitioning to less frequent appointments could decrease patient burden and health system costs. The objectives of this pilot study are to explore the feasibility and acceptability of (1) reducing the time to DSD from 12 to 6 months after antiretroviral therapy (ART) initiation,and (2) reducing the number of suppressed viral loads required to enter DSD from two to one. Methods and analyses The present study is a pilot, unblinded trial taking place in three health facilities in Kigali, Rwanda. Current Rwandan guidelines require PLHIV to be on ART for ≥12 months with two consecutive suppressed viral loads in order to transition to less frequent appointments. We will randomise 90 participants to one of three arms: entry into DSD at 6 months after one suppressed viral load (n=30), entry into DSD at 6 months after two suppressed viral loads (n=30) or current standard of care (n=30). We will measure feasibility and acceptability of this intervention; clinical outcomes include viral suppression at 12 months (primary outcome) and appointment attendance (secondary outcome). Ethics and dissemination This clinical trial was approved by the institutional review board of Albert Einstein College of Medicine and by the Rwanda National Ethics Committee. Findings will be disseminated through conferences and peer-reviewed publications, as well as meetings with stakeholders. Trial registration number NCT04567693.
AB - Introduction Current HIV guidelines recommend differentiated service delivery (DSD) models that allow for fewer health centre visits for clinically stable people living with HIV (PLHIV). Newly diagnosed PLHIV may require more intensive care early in their treatment course, yet frequent appointments can be burdensome to patients and health systems. Determining the optimal parameters for defining clinical stability and transitioning to less frequent appointments could decrease patient burden and health system costs. The objectives of this pilot study are to explore the feasibility and acceptability of (1) reducing the time to DSD from 12 to 6 months after antiretroviral therapy (ART) initiation,and (2) reducing the number of suppressed viral loads required to enter DSD from two to one. Methods and analyses The present study is a pilot, unblinded trial taking place in three health facilities in Kigali, Rwanda. Current Rwandan guidelines require PLHIV to be on ART for ≥12 months with two consecutive suppressed viral loads in order to transition to less frequent appointments. We will randomise 90 participants to one of three arms: entry into DSD at 6 months after one suppressed viral load (n=30), entry into DSD at 6 months after two suppressed viral loads (n=30) or current standard of care (n=30). We will measure feasibility and acceptability of this intervention; clinical outcomes include viral suppression at 12 months (primary outcome) and appointment attendance (secondary outcome). Ethics and dissemination This clinical trial was approved by the institutional review board of Albert Einstein College of Medicine and by the Rwanda National Ethics Committee. Findings will be disseminated through conferences and peer-reviewed publications, as well as meetings with stakeholders. Trial registration number NCT04567693.
KW - HIV & AIDS
KW - clinical trials
KW - international health services
UR - http://www.scopus.com/inward/record.url?scp=85105052904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105052904&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-047443
DO - 10.1136/bmjopen-2020-047443
M3 - Article
C2 - 33895720
AN - SCOPUS:85105052904
SN - 2044-6055
VL - 11
JO - BMJ Open
JF - BMJ Open
IS - 4
ER -